Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
Kyowa Kirin said on March 3 that it is discontinuing all global clinical trials of its investigational atopic dermatitis therapy rocatinlimab, a blockbuster hopeful that was also being studied for prurigo nodularis and asthma. Clinical studies identified cases of suspected…
To read the full story
Related Article
- Kyowa Kirin Keeps Long-Term KPIs despite OX40 Setback, Ups 2026 Core Profit Outlook
May 11, 2026
- Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
March 5, 2026
- Kyowa Kirin Aims to Raise Core Margin to 30% on Late-Stage Launches
February 12, 2026
- Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
BUSINESS
- Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
October 2, 2026
- Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
- Bayer Takes Dialogue-Driven Innovation Model Nationwide
October 1, 2026
- Chugai to Set Up South Korea Unit, Take Sales In-House
October 1, 2026
- Daito Reveals Meiji, DBJ as Partners in Kyorin Generics JV
October 1, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…